InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Recombinant human IL-1β protein | Diverse viral proteases activate the NLRP1 inflammasome. | 2021 | Elife | Tsu B.T. et al. | DOI: 10.7554/eLife.60609 |
QUANTI-Blue™ | Diverse viral proteases activate the NLRP1 inflammasome. | 2021 | Elife | Tsu B.T. et al. | DOI: 10.7554/eLife.60609 |
Human IL-1α & IL-1β Reporter HEK 293 Cells | Diverse viral proteases activate the NLRP1 inflammasome. | 2021 | Elife | Tsu B.T. et al. | DOI: 10.7554/eLife.60609 |
TLR4 agonist preparation - MPLA-SM | Matured Tolerogenic Dendritic Cells Effectively Inhibit Autoantigen Specific ... | 2021 | Front Immunol | Jansen M.A. et al. | DOI: 10.3389/fimmu.2019.02068 |
J774-Dual™ Cells | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
LyoVec™ | Inhibitor of growth protein 3 epigenetically silences endogenous retroviral e... | 2021 | Nucleic Acids Res | Song Y. et al. | DOI: 10.1093/nar/gkab1070 |
Poly(I:C) (HMW) / LyoVec™ | Inhibitor of growth protein 3 epigenetically silences endogenous retroviral e... | 2021 | Nucleic Acids Res | Song Y. et al. | DOI: 10.1093/nar/gkab1070 |
Recombinant human IFN-α proteins | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
THP1-Dual™ Cells | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
2'3'-cGAMP | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
QUANTI-Blue™ | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
5'ppp-dsRNA | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
QUANTI-Luc™: Luciferase Detection Reagent | Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy ris... | 2021 | J Immunother Cancer | Sprooten J. et al. | DOI: 10.1136/jitc-2021-003609 |
Puromycin | MAGEH1 interacts with GADD45G and induces renal tubular cell apoptosis. | 2021 | PLoS One | Shin G.T. et al. | DOI: 10.1371/journal.pone.0260135 |
MycoStrip® - Mycoplasma Detection Kit | MAGEH1 interacts with GADD45G and induces renal tubular cell apoptosis. | 2021 | PLoS One | Shin G.T. et al. | DOI: 10.1371/journal.pone.0260135 |
TLR4 agonist preparation - MPLA-SM | An allergen-fused dendritic cell-binding peptide enhances in vitro proliferat... | 2022 | Vet Immunol Immunopathol | Ziegler A et al. | DOI: 10.1016/j.vetimm.2021.110351 |
ODN D-SL03 | An allergen-fused dendritic cell-binding peptide enhances in vitro proliferat... | 2022 | Vet Immunol Immunopathol | Ziegler A et al. | DOI: 10.1016/j.vetimm.2021.110351 |
Puromycin | Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal infla... | 2021 | Nat Commun | Ryzhakov G. et al. | DOI: 10.1038/s41467-021-27038-5 |
WGP - Whole Glucan Particles | Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal infla... | 2021 | Nat Commun | Ryzhakov G. et al. | DOI: 10.1038/s41467-021-27038-5 |
Recombinant anti-mouse PD-1 antibody - Clone RMP1-14 (D265A) | Sharpening up tumor microenvironment to enhance the efficacy of immune checkp... | 2021 | Cancer Immunol Immunother | Tseng J.C. et al. | DOI: 10.1007/s00262-021-03062-8 |